{"preliminary_commentary":{"by_channel":{"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05506943\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"COMPANION-002","nct_id":"NCT05506943","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=companion-002-nct05506943. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"CTX-009 plus Paclitaxel","type":"EXPERIMENTAL"},{"description":"Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.","label":"Paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-08-31","type":"ESTIMATED"},"conditions":["Biliary Tract Cancer","Cholangiocarcinoma","Gall Bladder Cancer","Ampullary Cancer"],"enrollment":{"count":168,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CTX-009","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-02","lead_sponsor":"Compass Therapeutics","official_title":"A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2027-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Best Overall Response","timeFrame":"From randomization to treatment discontinuation for any reason, average 6 months"}],"references":[{"citation":"Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024;20(30):2241-2248. doi: 10.1080/14796694.2024.2351351. Epub 2024 Jun 4.","pmid":"38861293","type":"DERIVED"}],"start_date":{"date":"2023-01-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","url":"https://clinicaltrials.gov/study/NCT05506943"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/companion-002-nct05506943"}